(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ

References

• Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 2012;124(1):164–169.
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. Cancer J Clin. 2011;61(3):183–203.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.
   PubMed Web of Science ®Google Scholar
• Guarneri V, Piacentini F, Barbieri E, et al. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010;117(2):152–158.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Wilkie KP, Hahnfeldt P. Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy. Cancer Res. 2013;73(12):3534–3544.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010;59(10):1593–1600.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3–8.
   PubMed Web of Science ®Google Scholar
• Ochando JC, Chen SH. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res. 2012;54(1–3):275–285.
   PubMed Web of Science ®Google Scholar
• Bronte V, Serafini P, Mazzoni A, et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003;24(6):302–306.
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68–77.
   PubMed Web of Science ®Google Scholar
• Solito S, Marigo I, Pinton L, et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann NY Acad Sci. 2014;1319(1):47–65.
   PubMed Web of Science ®Google Scholar
• De Henau O, Rausch M, Winkler D, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature. 2016;539(7629):443–447.
   PubMed Web of Science ®Google Scholar
• Zhou XF, Tong GT, Wang XW, et al. Anti-proliferative constituents from Selaginella moellendorffii Hieron. Nat Prod Commun. 2016;11:623–626.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zhang R, Peng Z, et al. Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. J Bone Oncol. 2017;9:59–64.
   PubMed Web of Science ®Google Scholar
• Yang L, Wang B, Qin J, et al. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. Immunopharmacol Immunotoxicol. 2018;40(1):91–97.
   PubMed Web of Science ®Google Scholar
• Sahin E, Haubenwallner S, Kuttke M, et al. Macrophage PTEN regulates expression and secretion of arginase I modulating innate and adaptive immune responses. J Immunol. 2014;193(4):1717–1727.
   PubMed Web of Science ®Google Scholar
• Cui W, Cai Y, Zhou X. Advances in subunits of PI3K class I in cancer. Pathology. 2014;46(3):169–176.
   PubMed Web of Science ®Google Scholar
• Di Mitri D, Toso A, Alimonti A. Molecular pathways: targeting tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. Clin Cancer Res. 2015;21(14):3108–3112.
   PubMed Web of Science ®Google Scholar
• Arihara F, Mizukoshi E, Kitahara M, et al. Increase in CD14 + HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013;62(8):1421–1430.
   PubMed Web of Science ®Google Scholar
• Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2):721s–7726.
   PubMed Web of Science ®Google Scholar
• Umansky V, Blattner C, Gebhardt C, et al. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines. 2016;4(4):36–51.
   Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148–2157.
   PubMed Web of Science ®Google Scholar
• Tobin RP, Jordan KR, Robinson WA, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018;63:282–291.
   PubMed Web of Science ®Google Scholar
• Marshall NA, Galvin KC, Corcoran AM, et al. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ + IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res. 2012;72(3):581–591.
   PubMed Web of Science ®Google Scholar
• Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501–1509.
   PubMed Web of Science ®Google Scholar
• Chiou WF, Don MJ, Liao JF, et al. Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways. Eur J Pharmacol. 2011;650(1):102–109.
   PubMed Web of Science ®Google Scholar
• Davis RJ, Moore EC, Clavijo PE, et al. Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kδ/γ. Cancer Res. 2017;77(10):2607–2619.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, Li H, et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 2016;539(7629):437–442.
   PubMed Web of Science ®Google Scholar
• Ali K, Soond DR, Pineiro R, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014;510(7505):407–411.
   PubMed Web of Science ®Google Scholar